Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks


Objective: To evaluate the continued safety and durability of clinical response in patients with ankylosing spondylitis receiving etanercept.

Methods: 277 patients who had participated in a previous randomised, double blind, placebo controlled 24 week trial were eligible to continue in this open label extension study. All patients who enrolled in the open label extension (n = 257) received subcutaneous etanercept 25 mg twice weekly for up to 72 weeks, for a combined 96 weeks of cumulative trial and open label experience. For the patients who had received etanercept for 24 weeks in the double blind trial, this represented almost 2 years of continuous etanercept treatment.

Results: Patients continuing etanercept treatment had a sustained response for almost 2 years, with 74% achieving an ASAS20 response after 96 weeks of etanercept treatment. Patients who had received placebo in the preceding double blind trial had similar responses, with 70% of patients attaining an ASAS20 response after 24 weeks of etanercept treatment and 78% achieving an ASAS20 response after 72 weeks. Improved spinal mobility was seen in both groups. Etanercept was well tolerated in patients treated for up to 96 weeks.

Conclusion: The subcutaneous administration of twice weekly doses of etanercept provided sustained durability of response in the improvement of signs and symptoms of ankylosing spondylitis for nearly 2 years.

At RCT enrolment, patients had active AS and fulfilled the modified New York criteria. Detailed information on the inclusion and exclusion criteria for the RCT have been presented elsewhere. In this extension study, patients were allowed to continue to take hydroxychloroquine, sulfasalazine, or methotrexate and/or to change the doses at the discretion of the principal investigator at each site.

All patients who completed the RCT were eligible for inclusion in this extension study. Additionally, patients from the RCT who had dropped out at or after 12 weeks because of lack of efficacy were eligible to enrol in the extension study, provided that the patient had returned for all the required follow up visits. Patients who had discontinued because of adverse events were eligible to enrol provided that the event had resolved and that the clinical investigator still considered the patient a candidate for etanercept treatment.

Study design and drug

Previously, patients received either subcutaneous (SC) etanercept 25 mg (n = 138) or placebo (n = 139) twice weekly; in this extension study, all patients received SC etanercept 25 mg twice weekly for up to 72 weeks (fig 1). For patients who had received etanercept for 24 weeks in the RCT, this represented almost 2 years of continuous etanercept treatment. The study drug was supplied as a sterile lyophilised powder containing 25 mg etanercept (Enbrel; Immunex, subsidiary of Amgen) for reconstitution and self administered SC injection.

Abbreviations: AS, ankylosing spondylitis; ASAS, ASsessment in Ankylosing Spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Function Index; CRP, C reactive protein; PPD, purified protein derivative; RCT, randomised clinical trial; SC, subcutaneous


See end of article for authors’ affiliations

Correspondence to: Assistant Professor J C Davis, University of California, San Francisco, 533 Parnassus Ave Rm U 383 Box 0633, San Francisco, California, USA; jdc@med.ucsf.edu

Accepted 3 April 2005
Published Online First 26 May 2005

Efficacy

The primary outcome of the preceding RCT was a comparison between the proportion of patients attaining an ASAS 20 response at 12 weeks among patients receiving etanercept and patients receiving placebo. To qualify as an ASAS 20 responder, a patient had to show an improvement of 20%, equating to a minimum improvement of 10 units on a 100 mm visual analogue scale in at least three of four measures: patient’s global assessment; pain; physical function; and/or inflammation, with no deterioration (defined as a 20% worsening and absolute change of at least 10 units) in the fourth criterion.8 Physical function was measured by the average of the final two questions on the BASFI assessing severity and duration of morning stiffness10 (range 0 = easy to perform tasks to 100 = impossible to perform tasks) and inflammation was represented by the average of the final two questions on the BASDAI assessing severity and duration of morning stiffness10 (range 0 = none to 100 = very severe).

The durability of response in those patients continuing etanercept from the RCT, as assessed by the proportion of ASAS 20 responders at the end of 72 weeks of open label treatment, was determined. Secondary outcome measures included achievement of the ASAS 50 (50% and 20 units improvement in the four domains for ASAS 20 criteria, without worsening in the remaining domain) and ASAS 70 (70% improvement and 30 units in the same four domains, without worsening in the remaining domain). Other outcome measures included the effect of etanercept treatment on nocturnal and total back pain, measurements of spinal mobility (chest expansion, modified Schober’s index, and occiput to wall measurements), peripheral joint counts, acute phase reactants, and assessor’s global assessment.

We also incorporated the two alternative definitions of the ASAS criteria, based on those set forward by the ASAS international working group, ASAS for Disease Controlling Anti-Rheumatic Therapies: ASAS 40 response and ASAS 5/6.11

The ASAS 40 response requires a 40% improvement relative to baseline plus absolute improvement of at least 20 units in any three of four of the ASAS criteria listed above, with no worsening in the remaining criterion.

Our modification of the ASAS 5/6 required a 20% improvement in five of six criteria—the four criteria of the ASAS response, a measure of spinal mobility, and an acute phase reactant—with no worsening in the remaining criterion. In addition, a 20% improvement in patient’s global assessment; pain; physical function; and/or inflammation was required to equate to an absolute improvement of at least 10 units. This definition is slightly more restrictive than the ASAS 5/6 proposed by Brandt et al12 and is likely to yield a slightly smaller proportion of responders than would have been seen with the original definition. The measures of spinal mobility and acute phase reactant prespecified in the statistical analysis plan were chest expansion and C reactive protein (CRP), respectively. Brandt et al used lumbar lateral flexion as the measure of spinal mobility.11

Safety evaluation

All patients who received at least one dose of the study drug in the double blind or open label periods were evaluated for safety. The following variables were assessed: results of a physical examination, vital signs, haematology and chemistry profiles, urine analysis, antibodies against etanercept, premature discontinuation, adverse events, serious adverse events, and deaths on study. Adverse events and abnormal laboratory values were graded on a scale derived from the National Cancer Institute Common Toxicity Criteria (common terminology criteria for adverse events available online at http://ctep.cancer.gov, accessed 18 May 2005). Serious adverse events were defined as any events that resulted in death, a life threatening adverse experience, inpatient hospitalisation or prolongation of existing hospitalisation, a persistent or major disability/incapacity, or a congenital anomaly/birth defect.

Statistical analysis

The percentage of responders as determined by the ASAS response criteriaa was determined over time by original treatment group. Efficacy analyses are reported without statistical inference between treatment groups. For both groups of patients, measurements from the baseline visit of the RCT were used as baseline values. Data were combined with the results of the preceding RCT to assess the durability of the ASAS response rates. Efficacy summary tables include all subjects with data available at each given time point.

RESULTS

Patients

Of the 277 patients who were dosed and analysed in the RCT, 257 patients started the extension study (fig 1). Ten patients in each RCT group did not enrol in the open label trial. Twelve patients receiving etanercept had discontinued during the RCT. Of these, three patients re-enrolled in the open label trial: two patients who had discontinued at or after 12 weeks owing to a lack of efficacy and one patient who had discontinued because of an adverse event. One patient in

![Figure 1](http://www.annrheumdis.com)
the etanercept group who had completed the double blind trial declined to enrol in the open label trial (patient refusal). Nineteen patients receiving placebo had discontinued during the RCT. Of these, eight patients who had discontinued because of lack of efficacy enrolled in the open label trial, as did one patient who had discontinued because of an adverse event.

Baseline demographic characteristics of the group who enrolled in the open label extension were therefore very similar to those of the RCT, with a predominantly male (75%) and white (93%) population. The mean age of the group was 41.6 years (range 18–70 years), with a mean disease duration of 10.7 years (range 0.5–35.8). About one third (31.5%) of patients were taking concomitant disease modifying anti-rheumatic drug treatment, including sulfasalazine (21.8%), methotrexate (11.3%), and hydroxychloroquine (1.6%). At baseline, the mean (SD) patient global assessment was 63.3 (17.6) and the mean (SD) BASFI was 54.0 (20.6).

One hundred and twenty eight of the patients who enrolled were from the etanercept arm of the preceding trial; the other 129 began etanercept at week 0 of the open label extension study. Two hundred and nine patients received at least 72 weeks of etanercept treatment (104 patients continuing etanercept from the RCT and 105 patients starting etanercept in the open label extension), and 95 received a full 96 weeks.

Sixty seven patients receiving etanercept discontinued (fig 1). This included 10 patients who received etanercept in the RCT but did not enrol in the open label extension. Figure 1 lists the reasons for discontinuation.

**Table 1** Spinal mobility measures after extended etanercept exposure*

<table>
<thead>
<tr>
<th>Spinal Mobility Measure</th>
<th>RCT trial arm</th>
<th>Etanercept</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Occiput to wall measurement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCT baseline</td>
<td>5.4 (0.5)</td>
<td>5.0 (0.6)</td>
<td></td>
</tr>
<tr>
<td>(n = 128)</td>
<td>(n = 129)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 96 (72 weeks of open label)</td>
<td>4.0 (0.6)*</td>
<td>4.6 (0.7)*</td>
<td></td>
</tr>
<tr>
<td>(n = 95)</td>
<td>(n = 105)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Improvement</td>
<td>1.5 (0.3)</td>
<td>0.3 (0.4)</td>
<td></td>
</tr>
<tr>
<td>Median improvement</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Chest expansion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCT baseline</td>
<td>3.4 (0.2)</td>
<td>3.2 (0.2)</td>
<td></td>
</tr>
<tr>
<td>(n = 128)</td>
<td>(n = 129)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 96 (72 weeks of open label)</td>
<td>4.0 (0.2)†</td>
<td>3.5 (0.2)†</td>
<td></td>
</tr>
<tr>
<td>(n = 95)</td>
<td>(n = 105)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Improvement</td>
<td>0.7 (0.2)</td>
<td>0.2 (0.2)</td>
<td></td>
</tr>
<tr>
<td>Median improvement (range)</td>
<td>0.5</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Modified Schober’s index</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCT baseline</td>
<td>3.1 (0.2)</td>
<td>3.0 (0.1)</td>
<td></td>
</tr>
<tr>
<td>(n = 128)</td>
<td>(n = 129)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 96 (72 weeks of open label)</td>
<td>3.5 (0.2)†</td>
<td>3.2 (0.1)†</td>
<td></td>
</tr>
<tr>
<td>(n = 95)</td>
<td>(n = 105)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Improvement</td>
<td>0.5 (0.1)</td>
<td>0.2 (0.1)</td>
<td></td>
</tr>
<tr>
<td>Median improvement</td>
<td>0.5</td>
<td>0.3</td>
<td></td>
</tr>
</tbody>
</table>

*Data presented are mean (SE) unless otherwise noted; †total of 96 weeks of etanercept: 24 weeks in RCT and 72 weeks of open label treatment; *total of 72 weeks of etanercept: 24 weeks of placebo in RCT and 72 weeks of etanercept open label.
Durability of response

Patients who had received placebo in the preceding RCT switched to etanercept 25 mg twice weekly at the beginning of the open label period. Response in these patients was rapid and sustained. After receiving 24 weeks of etanercept treatment in the open label period, 70% of these patients had achieved an ASAS 20 response, compared with 57% of etanercept patients who had achieved an ASAS 20 response at week 24 of the RCT. Improvements were seen in all levels of ASAS response in those who entered the open label extension study (fig 2). All mean measures of spinal mobility, including chest expansion, occiput to wall measurement, and modified Schober’s index, also improved in this group by the end of 72 weeks of etanercept treatment (table 1).

Patients who had received etanercept in the preceding RCT and enrolled in the open label extension study showed continued and improved ASAS response for up to 2 years of treatment with etanercept (fig 2). At week 24 of the RCT, 57% of etanercept patients had achieved an ASAS 20 response; after an additional 72 weeks of open label etanercept (week 96, fig 2), 74% (70/95) of patients had achieved an ASAS 20 response. After 96 weeks of etanercept treatment, almost half (46%) of these patients had attained an ASAS 70 response. All three mean and two of three median measures of spinal

<table>
<thead>
<tr>
<th>RCT trial arm</th>
<th>Etanercept</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCT Baseline (n = 128)</td>
<td>63.2 (1.5)</td>
<td>46.3 (1.6)</td>
</tr>
<tr>
<td>Week 96 of etanercept (n = 95)</td>
<td>26.6 (2.6)</td>
<td>28.4 (2.3)</td>
</tr>
<tr>
<td>Placebo Baseline (n = 129)</td>
<td>61.7 (1.8)</td>
<td>46.7 (1.8)</td>
</tr>
<tr>
<td>Week 72 of etanercept (n = 105)</td>
<td>24.3 (2.6)</td>
<td>27.3 (2.6)</td>
</tr>
<tr>
<td>CRP</td>
<td>51.1 (1.8)</td>
<td>56.8 (1.8)</td>
</tr>
<tr>
<td>Modified Schober's index</td>
<td>60.9 (1.9)</td>
<td>65.3 (1.8)</td>
</tr>
</tbody>
</table>

*Values are mean (SE) unless otherwise indicated; †consisting of 72 weeks of open label etanercept and 24 weeks of RCT etanercept; ‡consisting of 72 weeks of open label etanercept; ††average of the scores for the last two questions of the BASDAI on duration and intensity of morning stiffness.

Figure 3
(A) Percentage of patients who attained the modified ASAS 5/6 (20% improvement in five of six criteria—patient’s global assessment, pain, physical function, inflammation, a measure of spinal mobility, and an acute phase reactant—with no worsening in the remaining criterion. In addition, improvement in patient’s global assessment, pain, physical function, and/or inflammation by at least 10 units). (B) Percentage of patients who attained ASAS 40 (40% improvement relative to baseline plus absolute improvement of at least 20 units in any three of four of patient’s global assessment, pain, physical function, and/or inflammation, with no worsening in the remaining criterion).
mobility in patients who had received etanercept in the RCT showed persistent improvement from baseline (table 1). In both these patients and patients who had received placebo in the RCT, the subgroup of patients with limited spinal mobility (defined as baseline occiput to wall ≥ 70; baseline chest expansion score < 2.5; or baseline Schober’s index < 5) showed positive improvements in all mean and all median measures of spinal mobility (data not shown).

Additional outcomes included the individual components of the ASAS response criteria and CRP (table 2). The group of patients who had received placebo in the RCT improved on all measures. The group of patients who had received etanercept in the preceding RCT demonstrated sustained benefit and, in some cases, continued improvement. In a more stringent definition of response, both groups of patients experienced disease improvement as measured by the ASAS 40 and modified ASAS 5/6 response criteria (fig 3).

**Safety**

Most adverse events reported were of mild or moderate intensity; table 3 lists those that occurred in ≥ 5% of patients. Two events occurred in two patients during the open label extension that were considered to be life threatening: an idiopathic third degree heart block and a pulmonary embolus, both of which the investigators considered unrelated to etanercept.

No deaths were reported in either the RCT or the open label extension.

Some of the extra-articular features of the spondyloarthropathies were also noted as adverse events during the trial; patients with a history of these features were not excluded from the trial. Twenty-six patients experienced uveitis or iritis, including 13 patients previously receiving placebo and 13 patients continuing etanercept from the RCT. Four of these patients had reported iritis or uveitis during the RCT and most (14/22) others had a pre-trial history of uveitis or iritis. Colitis was reported in five patients (including one case due to C difficile), ileitis was reported in two patients, and there were single reported cases of psoriasis and balanitis.

Five patients experienced serious infectious episodes after starting etanercept. All of these episodes resolved. One patient discontinued because of a non-serious infectious event (otitis media and a furuncles) and one patient discontinued because of a serious infectious event (a flare of hepatitis B in a foreign-born person).

One patient had a positive purified protein derivative (PPD) test but had none of the signs or symptoms associated with tuberculosis; it was unclear from the case report forms why the PPD test had been performed. Two cases of herpes zoster were reported.

Five patients discontinued as a result of laboratory abnormalities. One patient had grade 3 increases in liver enzymes on more than one test date; one patient had grade 3 results from alanine aminotransferase and aspartate aminotransferase determinations on the same date, with all other test dates falling within normal ranges. Two patients had single cases of laboratory abnormalities without any associated adverse events amid consistently normal readings: one patient had a single recorded grade 4 laboratory abnormality, with a platelet count of 3 × 10^11/l on study day 421 despite consistently registered platelet counts > 200 × 10^11/l on all other test dates (including study days 337 and 427), and another patient had a single grade 3 increase in liver enzymes on study day 250 (288 U/l) amid consistent test results < 40 U/l. The authors believe that these two abnormalities represent spurious laboratory results. A patient with a grade 3 abnormal lymphocyte count before starting the study received only 12 days of etanercept; on study day 63, the patient’s lymphocyte count was still grade 3. One additional patient had a grade 4 absolute neutrophil count at baseline that resolved to essentially normal values (toxicity grade 1) by study day 82.

**DISCUSSION**

Treatment of AS has largely consisted of non-steroidal anti-inflammatory drugs; most disease modifying antirheumatic drugs have limited efficacy on peripheral symptoms and are not effective in axial manifestations. Etanercept has already been seen to be effective in bringing about a rapid and significant improvement to patients with AS. The ability of etanercept to alter the loss of spinal mobility in these patients is of particular importance.

Patients continued to receive clinical benefit from etanercept in this extension study, including the maintenance of spinal mobility gains made during the RCT. Patients who switched from placebo to etanercept demonstrated improvement in the BASFI and all levels of ASAS response (20%, 50%, and 70%). Overall, the treatment effect in the two groups in the open label extension period was similar, regardless of whether placebo had been started first. Although the gains in spinal mobility in the group of patients who first received placebo may not be as strong as those seen in the original etanercept group, placebo patients as a group nevertheless recovered spinal mobility, as reflected in mean spinal mobility measurements.
Etanercept continued to be well tolerated in this open label extension study, with no increases in rates of adverse events or serious adverse events over the clinical trial experience. Importantly, none of the most serious safety concerns that have been linked with some tumour necrosis factor inhibitors—tuberculosis, drug-induced lupus, demyelinating diseases such as multiple sclerosis, and lymphomas—were reported in patients receiving etanercept either during the RCT or the subsequent open label extension study. The safety profile was similar to that in the RCT, as well as in studies in other disease states such as rheumatoid arthritis,12 13 psoriatic arthritis,14 and psoriasis,15 16 suggesting that the safety profile of etanercept is similar in the short and long terms. In the 24 weeks of the RCT, 11 patients reported uveitis or iritis; after 72 weeks of etanercept in the open label period, 26 patients reported uveitis or iritis (including four of the patients who had reported uveitis/iritis in the RCT). Similarly, five patients reported colitis or ileitis in the 24 week RCT and seven reported colitis or ileitis in the 72 week extension. Although the RCT and this study were not powered to discern efficacy in the prevention of uveitis/iritis or colitis, these results suggest that etanercept does not increase the incidence in 72 weeks over what is expected in this population.

One obvious limitation of this study is that the comparator’s analysis allows for the attrition of patients over time, which can have the effect of enriching the population for responders. However, this analysis has the strength of examining the ability of etanercept to deliver sustained benefit, which here is demonstrated for nearly 2 years. In a patient population with a need for chronic treatment to prevent progressive disability, the ability of a drug to provide sustained benefit coupled with long term tolerability is critically important. Of note, analyses using the last observation carried forward for patients who dropped out yielded proportions of responders similar to those measured by the ASAS 20, ASAS 40, ASAS 50, ASAS 70, and ASAS 5/6.

Taken together, these data demonstrate the continued effectiveness and tolerability of etanercept in patients with AS. Current experience demonstrates nearly 2 years of sustained benefit. We believe that the improvement of spinal mobility is an especially promising effect of etanercept treatment; imaging studies may shed more light on the effect of etanercept on structural damage.

ACKNOWLEDGEMENTS
We thank Elizabeth HZ Thompson, PhD, for assistance with preparation of the manuscript. This study was funded by Immunex Corporation, a wholly owned subsidiary of Amgen Inc, and by Wyeth Research.

AUTHORS’ AFFILIATIONS
J C Davis, Division of Rheumatology, University of California, San Francisco, San Francisco, USA
D M van der Heijde, Department of Rheumatology, University Hospital Maastricht, Maastricht, The Netherlands

J Braun, Rheumazentrum, Ruhrgebiet, Landgraaf, Germany
M Dougdas, Rhumatologie B, Hopital Cochin, Paris, France
J Cush, Arthritis Consultation Center, Presbyterian Hospital of Dallas, Dallas, USA
D Clegg, Division of Rheumatology, University of Utah Health Sciences Center, Salt Lake City, USA
R D Innan, Toronto Western Hospital, Toronto, Ontario, Canada
A Kivitz, Clinical Research, Altoona Center for Clinical Research, Duncansville, USA
L Zhou, A Solinger, W Tsuji, Development, Amgen, Thousand Oaks, USA

REFERENCES
6 Brandt JL, Khoury CJ, Yu, USA